The Genesys Hurley Cancer Institute had increased its comprehensive range of radiation oncology treatment services adding the TrueBeam STx linear accelerator and BrainLab Novalis to its arsenal of treatment capabilities include the Trilogy Linear Accelerator, Brilliance Big Bore CT Simulator, ACQSim CT Simulator, Treatment Planning Systems and High Dose Brachytherapy along with the recent addition of the TrueBeam STxRecently the Genesys Hurley Cancer Institute has replaced its 23 EX linear accelerator with a TrueBeam STX/Novalis linear accelerator. Patients at the Genesys Hurley Cancer Institute can now benefit from a new linear accelerator capable of delivering many forms of advanced treatment, including image-guided radiotherapy, intensity-modulated radiotherapy, respiratory gating and VMAT / RapidArc radiotherapy.
The new TrueBeam STx system compliments our Trilogy system at the Genesys Hurley Cancer Institute in providing advanced solutions for treating cancer. A game-changing leap in innovation. It performs many different treatment techniques such as IMRT (Intensity Modulated Radiation Therapy), IGRT (Image Guided Radiation Therapy), Stereotactic Body Radiotherapy (SBRT) and Stereotactic Radiosurgery (SRS). With its power and flexibility, clinicians can provide and design treatments that is best suited for patients’ individual circumstances.
- Precession is measures in increments of less than a millimeter
- TrueBeam STx’s functionally provides for the acquisition of a cone beam CT for set-up accuracy and verification
- A high definition multileaf collimator shapes the beam with 120 computer controlled “leaves” or “fingers” that can create multiple different shapes and sizes. The leaves shape the beam to match the 3-D shape of the tumor. They leaves can move and change during treatment to target the tumor.
- Real-time imaging tools allows clinicians to see the tumor they are about to treat.
- The system is able to provide a gated option for synchronizing beam delivery with respiration to help maintain accuracy as it targets tumor motion.